ストックスクリーナーアプリを入手
19.32
0.00%
0.02
前日終値:
$19.34
開ける：
$19.4
24時間の取引高:
682.88K
Relative Volume:
0.31
時価総額：
$3.57B
収益：
$797.73M
当期純損益:
$-325.77M
株価収益率:
-10.90
EPS:
-1.7725
ネットキャッシュフロー:
$-332.79M
1週間 パフォーマンス:
-12.65%
1か月 パフォーマンス:
-15.36%
6か月 パフォーマンス:
-56.36%
1年 パフォーマンス:
-48.69%
1日の値動き範囲:
$19.03
$19.86
1週間の範囲:
$19.03
$23.88
52週間の値動き範囲:
$19.03
$44.90
Legend Biotech Corp Adr Stock (LEGN) Company Profile
LEGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
19.31 | 3.57B | 797.73M | -325.77M | -332.79M | -1.7725 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.58 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.63 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.38 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.67 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 開始されました | Oppenheimer | Outperform |
| 2025-10-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-06-17 | 開始されました | Truist | Buy |
| 2024-05-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-05-23 | 開始されました | Deutsche Bank | Buy |
| 2024-04-17 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | Raymond James | Outperform |
| 2023-12-19 | 開始されました | Scotiabank | Sector Perform |
| 2023-11-06 | 開始されました | Goldman | Buy |
| 2023-05-25 | 開始されました | William Blair | Mkt Perform |
| 2023-05-22 | 開始されました | Daiwa Securities | Buy |
| 2023-03-29 | 開始されました | H.C. Wainwright | Buy |
| 2023-03-24 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-11-02 | 開始されました | Evercore ISI | Outperform |
| 2022-11-01 | 開始されました | Cowen | Outperform |
| 2022-10-31 | 開始されました | Guggenheim | Neutral |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-03-15 | 開始されました | Barclays | Overweight |
| 2022-01-31 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | 開始されました | Piper Sandler | Overweight |
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2020-07-01 | 開始されました | JP Morgan | Overweight |
| 2020-07-01 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Legend Biotech Corp Adr (LEGN) 最新ニュース
Legend Biotech (NASDAQ:LEGN) Price Target Lowered to $50.00 at HC Wainwright - Defense World
Legend Biotech (NASDAQ:LEGN) Shares Gap Down on Analyst Downgrade - Defense World
H.C. Wainwright lowers Legend Biotech stock price target on Q4 sales miss By Investing.com - Investing.com South Africa
H.C. Wainwright lowers Legend Biotech stock price target on Q4 sales miss - Investing.com India
Rakuten Investment Management Inc. Takes $7.58 Million Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech stock rating downgraded by TD Cowen on Carvykti concerns - Investing.com South Africa
Legend Biotech (NASDAQ:LEGN) Hits New 52-Week LowHere's Why - MarketBeat
Legend Biotech stock hits 52-week low at $20.15 - Investing.com
Legend Biotech (NASDAQ:LEGN) Given “Outperform” Rating at Royal Bank Of Canada - Defense World
Raymond James reiterates Outperform rating on Legend Biotech stock By Investing.com - Investing.com India
Raymond James reiterates Outperform rating on Legend Biotech stock - Investing.com
Legend Biotech stock rises as FDA draft guidance supports accelerated approval endpoints By Investing.com - Investing.com South Africa
Legend Biotech stock rises as FDA draft guidance supports accelerated approval endpoints - Investing.com
Algonquin Power & Utilities Corp. (NYSE:AQN) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Short Interest in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Expands By 23.3% - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Short Interest Up 23.3% in December - MarketBeat
Deutsche Bank reiterates Buy rating on Legend Biotech stock with $60 target - Investing.com
LEGN: CARVYKTI's rapid growth, clinical leadership, and pipeline innovation drive 2026 profitability goals - TradingView — Track All Markets
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN) - Finviz
Legend Biotech (NASDAQ:LEGN) Coverage Initiated by Analysts at Oppenheimer - Defense World
Legend Biotech (NASDAQ:LEGN) Trading Up 7.3%What's Next? - MarketBeat
Legend Biotech (NASDAQ:LEGN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Legend Biotech stock hits 52-week low at 21.16 USD - Investing.com
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Matthews International Capital Management LLC - MarketBeat
Connective Portfolio Management LLC Acquires New Holdings in Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Legend Biotech (LEGN) – Investment Analysts’ Recent Ratings Changes - Defense World
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - The Motley Fool
Here is Why Legend Biotech (LEGN) Offers Such Promising Upside - Finviz
Legend Biotech stock remains Overweight at Cantor Fitzgerald despite YTD decline By Investing.com - Investing.com South Africa
Legend Biotech stock remains Overweight at Cantor Fitzgerald despite YTD decline - Investing.com India
Legend Biotech (NASDAQ:LEGN) Reaches New 52-Week LowWhat's Next? - MarketBeat
Legend Biotech stock hits 52-week low at $22.27 - Investing.com
Squarepoint Ops LLC Grows Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Braidwell LP - MarketBeat
Jump Financial LLC Increases Stake in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Corporation (LEGN) is an Outperform on Multiple Myeloma Treatment CARVYKTI Prospects - Finviz
Nothing is Better Than Harrow Inc (HROW) stock at the moment - Setenews
Ready to Jump After Recent Trade: Venture Global Inc (VG) - setenews.com
Stempoint Capital LP Takes $9.59 Million Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech stock remains Outperform at RBC despite competitive threats By Investing.com - Investing.com South Africa
Legend Biotech (NASDAQ:LEGN) Trading Down 4.7%Time to Sell? - MarketBeat
Legend Biotech stock remains Outperform at RBC despite competitive threats - Investing.com
Federated Hermes Inc. Has $37.75 Million Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech (NASDAQ:LEGN) Sets New 12-Month LowWhat's Next? - MarketBeat
Legend Biotech stock hits 52-week low at $25.66 By Investing.com - Investing.com South Africa
Legend Biotech stock hits 52-week low at $25.66 - Investing.com
Legend Biotech stock maintains Outperform rating at RBC on Carvykti efficacy - Investing.com India
Legend Biotech Corporation Sponsored ADR $LEGN Shares Purchased by New York State Common Retirement Fund - MarketBeat
Schroder Investment Management Group Has $6.74 Million Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Corp Adr (LEGN) 財務データ
収益
当期純利益
現金流量
EPS
2.42%
1.57%
大文字化:
|
ボリューム (24 時間):